Palisade Bio, Inc. (PALI) stock forecast and price target
Price $1.12 · data as of November 13, 2026
12-month price target
Average target$8.70
Upside / downside+676.8%
Analysts10
ConsensusStrong buy
Low $5.00Average $8.70High $16.00
Gold marker: average target · white marker: today’s price ($1.12)
Analyst ratings
Strong buy 3Buy 7Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.24 | +18.8% | $444440 |
| Next fiscal year ends December 31, 2027 | $-0.33 | −35.9% | $0 |
| Next quarter ends December 31, 2026 | $-0.06 | — | $0 |
| Quarter after ends March 31, 2027 | $-0.08 | — | $0 |
Consensus of the analysts covering Palisade Bio, updated daily. In the last 30 days 2 estimates were raised and 5 lowered.
Frequently asked questions
What is the Palisade Bio stock price target?
The average 12-month target from 10 analysts is $8.70, 676.8% above the current price of $1.12 Targets range from $5.00 to $16.00.
Is Palisade Bio a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 7 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Palisade Bio expected to earn?
Analysts expect EPS of $-0.24 for the fiscal year ending December 31, 2026 and $-0.33 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.